Covered recipient · General Payments record
GERALD J KIVETT
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,649.19
- Reported across 195 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $325.26 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $64.22 | 3 |
| Novo Nordisk AS | $63.95 | 4 |
| Abbott Laboratories | $47.12 | 2 |
| Exact Sciences Corporation | $38.14 | 2 |
| PFIZER INC. | $36.91 | 2 |
| Amgen Inc. | $31.81 | 1 |
| Acerta Pharma LLC | $28.01 | 2 |
| Lilly USA, LLC | $15.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.73 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124899723 | CMS |
| Abbott Laboratories | $23.39 | 07/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124899725 | CMS |
| ABBVIE INC. | $22.79 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104082438 | CMS |
| ABBVIE INC. | $19.79 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104082440 | CMS |
| ABBVIE INC. | $21.64 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104082442 | CMS |
| Amgen Inc. | $31.81 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111620998 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.02 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104425047 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.99 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104571670 | CMS |
| Exact Sciences Corporation | $19.07 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114737251 | CMS |
| Exact Sciences Corporation | $19.07 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114737256 | CMS |
| Lilly USA, LLC | $15.10 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135007775 | CMS |
| Novo Nordisk Inc | $15.07 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097057354 | CMS |
| Novo Nordisk Inc | $20.04 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096673831 | CMS |
| Novo Nordisk Inc | $15.21 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097024811 | CMS |
| Novo Nordisk Inc | $13.63 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097105909 | CMS |
| PFIZER INC. | $22.33 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130918813 | CMS |
| PFIZER INC. | $14.58 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130928824 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.